Vanguard Capital Management
XBIT icon

Vanguard Capital Management’s XBiotech XBIT Stock Holding History

Vanguard Capital Management’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$460K Sell
200,182
-789
-0.4% -$1.91K ﹤0.01% 3724
2026
Q1 		$472K Buy
+200,971
New +$486K ﹤0.01% 3679

Other funds holding XBIT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.41B AUM 39.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Vanguard Capital Management's XBIT Position: Q2 2026 in Review

Vanguard Capital Management reduced its XBiotech (XBIT) stake by 0.39% in Q2 2026, selling an estimated $1.91K and leaving 200,182 shares worth $460K. The position accounts for ﹤0.01% of the portfolio, ranked #3724.

Vanguard Capital Management first reported a position in XBIT in Q1 2026 and has held it in 2 quarters since. The position peaked at $472K in Q1 2026. 33 funds tracked by Wall St. Rank hold XBIT as of Q2 2026.

  • Vanguard Capital Management held 200,182 shares of XBiotech worth $460K as of Q2 2026.
  • Vanguard Capital Management sold 789 XBiotech shares in Q2 2026, an estimated $1.91K.
  • XBiotech made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3724 holding.
  • Vanguard Capital Management first reported a position in XBiotech in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's XBiotech position peaked at $472K in Q1 2026.
  • 33 funds tracked by Wall St. Rank held XBiotech as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.